WASHINGTON, April 2, 2015 /PRNewswire/ -- ImmunoClin Corporation (OTC Markets: IMCL), a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.
This license is essential to enable ImmunoClin to conduct research on cannabinoids in its London laboratory. Following the agreements announced last year, ImmunoClin will initiate formulation work that will include Cannabis Science, Inc. (CBIS) proprietary cannabinol (CBN) based product under development for neurological disorders. The Company is collaborating with the multinational company Unistraw Holdings Pte. Ltd. (Unistraw) and will utilize the Unistraw's pharmaceutical delivery system to prepare the product for pre-clinical testing.
"As announced last September, ImmunoClin has met its commitment; the preliminary results are expected within the next several months," said Dr. Dorothy Bray, CEO and President of ImmunoClin Corporation.
About ImmunoClin Corporation
ImmunoClin Corporation is a healthcare company with principal corporate office located in Washington, D.C., USA and European headquarters and laboratories in central London, United Kingdom. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease. ImmunoClin holds multiple patents and trademarks on a global basis.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Dr. Dorothy Bray, Director, President & CEO
J. Scott Munro, CFO
Mobile: +1 778-987-4308